Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn


Healius rejects $2bn takeover bid

Emma Rapaport with AAP  |  07 Jan 2019Text size  Decrease  Increase  |  
Email to Friend

Australian hospital operator Healius has rejected an “opportunistic” $2.02 billion takeover offer from its largest shareholder, Jangho Hong Kong Holdings.

Jangho, which owns nearly 16 per cent of Healius (ASX: HLS), made an indicative cash offer of $3.25 per share on January 3, which saw an immediate 12 per cent share price spike for the company formerly known as Primary Health Care.

But on Monday Healius announced the offer was "opportunistic" and "fundamentally undervalues" the company, as well as being conditional on several regulatory approvals in both China and Australia including the Foreign Investment Review Board.

Healthcare Pathology

Healius shares were trading down -4.36 per cent at 11:16 AEST

As such, Healius chairman Rob Hubbard recommended shareholders take no action on the offer.

"The sources of funding are not apparent from the information provided by Jangho and the proposal is conditional on a number of regulatory approvals that are outside of the control of Jangho, including the approval of Chinese and Australian regulators," Healius said in a statement to the ASX.

Investing Compass
Listen to Morningstar Australia's Investing Compass podcast
Take a deep dive into investing concepts, with practical explanations to help you invest confidently.
Investing Compass

Morningstar equity analyst Daniel Ragonese characterised Jangho's original proposal to acquire Healius for $3.25 per share as "convenient" – given shares in Healius have been depressed over recent months.

The bid represents a 33.2 per cent premium to Healius's last closing price. This, however, is well below a peak of about $3.95 in March last year.

Jangho's bid falls more than 7 per cent short of Morningstar's $3.50 fair value estimate.

"It [would have been] a shrewd bit of business for the Chinese company if they manage to pull it off," Ragonese says.

Ragonese believes Healius offers more value to shareholders as a standalone business

"The firm's large-scale medical centres generated dependable earnings, and its pathology division in particular enjoys competitive advantages," he says.

"Healius is leveraged to growing demand from Australia's aging population, and increased government focus on preventative health should help drive demand in pathology and radiography divisions."

Healius shares were trading down -4.36 per cent from the previous day close at 11:16 AEST. However, at the current price of $2.36, stocks are up almost 18 per cent from a near three-year low of $2.23 on December 31.

Primary Health Care, founded 30 years ago by the late Edward Bateman and operates pathology, medical centres, IVF, imaging and day hospitals, changed its name to Healius as part of a rebrand late last year.

In its most recent company update published in October last year, Morningstar said it expected earnings per share growth of about 7 per cent a year on average during the next five years.

Healius is expected to report its first half results, performance and outlook in mid-February.

Price Chart | Healius Limited HLS

Healius price chart asx stock

. Emma Rapaport is a reporter for Morningstar Australia.

© 2022 Morningstar, Inc. All rights reserved. Neither Morningstar, its affiliates, nor the content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. This information is to be used for personal, non-commercial purposes only. No reproduction is permitted without the prior written consent of Morningstar. Any general advice or 'regulated financial advice' under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892), or its Authorised Representatives, and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information, refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). Our publications, ratings and products should be viewed as an additional investment resource, not as your sole source of information. Morningstar’s full research reports are the source of any Morningstar Ratings and are available from Morningstar or your adviser. Past performance does not necessarily indicate a financial product's future performance. To obtain advice tailored to your situation, contact a licensed financial adviser. Some material is copyright and published under licence from ASX Operations Pty Ltd ACN 004 523 782. The article is current as at date of publication.

Email To Friend